ID   HAP1 TMEM106B (-) 3
AC   CVCL_XU38
SY   HZGHC005877c010; TMEM106B knockout cell line 4bp deletion
DR   cancercelllines; CVCL_XU38
DR   Horizon_Discovery; HZGHC005877c010
DR   Wikidata; Q93973071
RX   PubMed=37545650;
CC   Group: Haploid karyotype cell line.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 22407; TMEM106B.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 13 fused to ABL1 exon 2 (b2a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_Y019 ! HAP1
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 02-05-24; Version: 10
//
RX   PubMed=37545650; DOI=10.12688/f1000research.131333.1;
RA   Ayoubi R., Fotouhi M., Southern K., Bhajiawala R., Fanti R., Prinos P.,
RA   McPherson P.S., Laflamme C.;
RT   "The identification of high-performing antibodies for transmembrane
RT   protein 106B (TMEM106B) for use in western blot, immunoprecipitation,
RT   and immunofluorescence.";
RL   F1000Research 12:308.1-308.10(2023).
//